NCNA
NuCana plc
stockNASDAQADR
nucana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. while these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. utilising our proprietary protide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.10 | 2026-10-09 | -9.99% | -2.150 |
| 1M | 1.30 | 2026-09-16 | -23.84% | -1.302 |
| 3M | 1.33 | 2026-07-16 | -25.56% | 1.249 |
| 6M | 2.13 | 2026-04-16 | -53.52% | 1.292 |
| 1Y | 5.14 | 2025-10-16 | -80.74% | 1.603 |
| 2Y | 370.00 | 2024-10-16 | -99.73% | — |
| 5Y | 13,350.00 | 2021-10-15 | -99.99% | 1.114 |
NuCana plc (NASDAQ:NCNA) stock price today is $0.99, and today's volume is 44,380. NCNA is down 2.931% today. The 30 day average volume is 179,674. NCNA market cap is $4.12M with 4.16M shares outstanding.